2024
A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients
Lee V, Parkinson R, Zahurak M, Cope L, Cercek A, Verheul H, Gootjes E, Lenz H, Iqbal S, Jones P, Baylin S, Rami V, Ahuja N, Khoueiry A, Azad N. A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS‐102 in irinotecan‐refractory metastatic colorectal cancer patients. International Journal Of Cancer 2024, 154: 1794-1801. PMID: 38312102, DOI: 10.1002/ijc.34845.Peer-Reviewed Original ResearchRefractory to irinotecanArm ATAS-102DNA methyltransferase inhibitorArm BRates of progression free survivalB. Median overall survivalEvidence of target modulationMetastatic colorectal cancer patientsResistant to systemic therapyTreatment related adverse eventsProgression free survivalPhase II studyPhase II trialKaplan-Meier ratesRelated adverse eventsColorectal cancer patientsFree survivalOverall survivalSystemic therapyAdverse eventsIrinotecanRegorafenibCancer patientsGuadecitabine
2017
Epigenetic therapy and chemosensitization in solid malignancy
Ronnekleiv-Kelly SM, Sharma A, Ahuja N. Epigenetic therapy and chemosensitization in solid malignancy. Cancer Treatment Reviews 2017, 55: 200-208. PMID: 28431263, DOI: 10.1016/j.ctrv.2017.03.008.Peer-Reviewed Original ResearchConceptsCombination therapyEpigenetic therapySpecific hematologic malignanciesCertain solid tumorsHistone deacetylase inhibitorsDurable responsesSystemic therapyPatient subsetsSolid malignanciesHematologic malignanciesOvarian cancerBreast cancerDNA methyltransferase inhibitorEpigenetic changesSolid tumorsDeacetylase inhibitorsStandard chemotherapeuticsTherapyClinical potentialCancer cellsTrialsNSCLCMalignancyMethyltransferase inhibitorHypermethylation patterns
2011
Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment
Poultsides GA, Huang LC, Cameron JL, Tuli R, Lan L, Hruban RH, Pawlik TM, Herman JM, Edil BH, Ahuja N, Choti MA, Wolfgang CL, Schulick RD. Duodenal Adenocarcinoma: Clinicopathologic Analysis and Implications for Treatment. Annals Of Surgical Oncology 2011, 19: 1928-1935. PMID: 22167476, PMCID: PMC3663711, DOI: 10.1245/s10434-011-2168-3.Peer-Reviewed Original ResearchConceptsDuodenal adenocarcinomaOverall survivalLymph nodesMultivariate analysisInvolved lymph nodesSmall bowel adenocarcinomaEffective systemic therapyFive-year survivalOnly independent predictorProlongs overall survivalAmpulla of VaterConclusionsThe prognostic significanceAdjuvant chemoradiationBowel adenocarcinomaUnderwent pancreaticoduodenectomySystemic therapyAdequate lymphadenectomyIndependent predictorsLocal recurrenceNodal metastasisClinicopathologic analysisPrognostic significanceClinicopathologic variablesRare cancersAdenocarcinoma